ObStructive Sleep Apnoea ManageMent in Older AdUlts with Overweight or ObEsity: A Randomized ClinicaL Trial (SAMUEL study)
Obstructive sleep apnoea is a common condition where breathing stops and starts during sleep. It is often linked with carrying excess weight, which can narrow the airway. The SAMUEL study is testing whether a medicine called Mounjaro (tirzepatide) can help reduce breathing pauses in older adults who are overweight or living with obesity. Mounjaro is already approved for diabetes and weight management. In this 24-week trial, participants will receive regular injections of Mounjaro to see how it affects their nighttime breathing, daytime sleepiness, overall sleep quality, and body weight. Researchers will also check whether the treatment supports memory and thinking skills. Taking part involves regular health checks and sleep assessments over about six months. The findings will help doctors better understand if weight-management injections are an effective way to relieve sleep apnoea symptoms.
Auf einen Blick
Worum geht es in dieser Studie?
Obstructive sleep apnoea happens when the muscles in the throat relax too much during sleep, temporarily blocking the airway. This causes loud snoring, interrupted sleep, and low oxygen levels, leaving people feeling exhausted during the day. In the UK, carrying excess weight is one of the most common causes, because extra tissue around the neck can press down on the breathing passage.
The SAMUEL clinical trial is exploring a new way to help manage this condition. Researchers are testing a weekly injection called Mounjaro (tirzepatide). While Mounjaro is already used to treat type 2 diabetes and support weight loss, doctors want to know if it can also treat sleep apnoea by helping people lose weight and reducing airway blockages.
Over a 24-week period, the study will monitor how many times breathing stops each hour at night. The team will also measure changes in body weight, daytime alertness, overall sleep quality, and memory. Because sleep apnoea can increase the risk of heart problems and memory issues in later life, finding effective, non-invasive treatments is especially important for older adults.
Wichtige Erkenntnisse
- The study tests whether Mounjaro can reduce sleep apnoea episodes in older adults who carry excess weight.
- Participation lasts for 24 weeks and involves weekly injections, sleep tests, and health reviews.
- Researchers will track sleep quality, daytime tiredness, body weight, and memory.
- Mounjaro is already approved for weight loss and diabetes, but common side effects can include an upset stomach.
- Joining is completely voluntary, and you can withdraw at any point.
Wer könnte berechtigt sein?
This trial is designed for older adults who have been diagnosed with obstructive sleep apnoea and are also living with overweight or obesity. Both men and women can take part.
While the study focuses on older adults, doctors will carry out individual health checks to make sure the trial is safe for each person. People who have certain other medical conditions or who are taking specific medicines that interact with Mounjaro may not be able to join.
A trial doctor or research nurse will review your full medical history and current symptoms to confirm whether this study is suitable for you.
Könnte diese Studie für Sie geeignet sein?
Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.
- I am an older adult.
- I have been diagnosed with obstructive sleep apnoea (or have symptoms like loud snoring and breathing pauses).
- I am living with overweight or obesity.
- I am willing to take a weekly injection for 24 weeks.
- I can attend regular clinic visits and take part in sleep tests.
Was beinhaltet die Teilnahme?
Taking part in the SAMUEL study lasts for about 24 weeks (around six months). If you join, you will be prescribed Mounjaro, which is given as a weekly injection under the skin using a pre-filled pen or vial. You will be shown how to use it safely at home.
Throughout the study, you will attend regular clinic visits. At these appointments, the research team will measure your weight, blood pressure, and general health. You will undergo sleep tests to count how often your breathing pauses at night. You will also complete simple memory tests and answer questionnaires about your sleep quality and daytime energy levels. The team will closely track any side effects to ensure you stay safe.
Potenzielle Risiken und Vorteile
Standorte (1)
- —UnbestätigtSpanien
Häufige Fragen
What is Mounjaro?
Mounjaro (tirzepatide) is an approved medicine that mimics natural gut hormones to help reduce appetite, regulate blood sugar, and support weight loss.
Wie wird das Medikament verabreicht?
It is given once a week as a small injection just under the skin, usually in the tummy or thigh. The study team will show you how to do this yourself.
Will taking part cost me anything?
No. The study medication, clinic visits, and all required tests are provided free of charge. Some studies also help with travel expenses.
Do I have to stop using my CPAP machine?
You should not stop any current sleep apnoea treatments without speaking to the study doctor. They will advise you on how to manage your normal treatments during the trial.
Kann ich die Studie verlassen, wenn ich meine Meinung ändere?
Yes. You can leave the trial at any time, for any reason, and your routine NHS medical care will continue as normal.
Wie Sie mehr erfahren können
Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.
Diskussion
Community-Diskussion
Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.